Home   About the Journal  Editorial Board  Online Journal   Publishing Ethics   Contact Us  Chinese Version
You are here:Home => Online Journal => Vol.35 No.5,2019 Multidisciplinary diagnosis and treatment of pancreatic cancer => Discussions by experts =>
Current status and perspectives of neoadjuvant therapy for pancreatic cancer
文章发布日期:2019年04月04日  来源:  作者:梁廷波  点击次数:974次  下载次数:255次
Adjust font size:Small regular big

【Abstract】:Abstract:The multimodality therapy with surgery as the core has gradually become the standard therapy for pancreatic cancer without distant metastasis. At present, many large-sample retrospective clinical studies have shown the value of neoadjuvant therapy in pancreatic cancer, and many international guidelines have recognized neoadjuvant therapy as a fundamental part of pancreatic cancer treatment. There are many ongoing large-scale, prospective, multi-center clinical trials, and the primary results of several studies have shown that neoadjuvant therapy can increase the radical resection rate of tumor and improve overall survival. However, there are still controversies over the value of neoadjuvant therapy in pancreatic cancer, especially resectable pancreatic cancer. In addition, no consensus has been reached on the selection of neoadjuvant regimen, the duration of neoadjuvant therapy, and neoadjuvant regimen after surgery for pancreatic cancer. It is believed that with the appearance of high-level evidence, neoadjuvant therapy will be widely used in pancreatic cancer.
【Key words】:pancreatic neoplasms; neoadjuvant therapy; chemotherapy, adjuvant; radiotherapy, adjuvant

Mail address: Editorial Office of Journal of Clinical Hepatology, 519 Dongminzhu Street, Changchun, Jilin, China Postal code: 130061 Tel:+86-431-88782542/3542
Journal of Clinical Hepatology Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号